Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS. Davis ID, et al. Among authors: hoffman ew. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702. doi: 10.1073/pnas.0403572101. Epub 2004 Jul 13. Proc Natl Acad Sci U S A. 2004. PMID: 15252201 Free PMC article. Clinical Trial.
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A. Jäger E, et al. Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8. doi: 10.1073/pnas.0606512103. Epub 2006 Sep 19. Proc Natl Acad Sci U S A. 2006. PMID: 16984998 Free PMC article. Clinical Trial.
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Atanackovic D, et al. Among authors: hoffman ew. J Immunol. 2004 Mar 1;172(5):3289-96. doi: 10.4049/jimmunol.172.5.3289. J Immunol. 2004. PMID: 14978137
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. Scott AM, et al. Among authors: hoffman ew. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. doi: 10.1073/pnas.0611693104. Epub 2007 Feb 28. Proc Natl Acad Sci U S A. 2007. PMID: 17360479 Free PMC article. Clinical Trial.
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Odunsi K, et al. Among authors: hoffman ew. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. doi: 10.1073/pnas.0703342104. Epub 2007 Jul 25. Proc Natl Acad Sci U S A. 2007. PMID: 17652518 Free PMC article. Clinical Trial.
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J. Nicholaou T, et al. Among authors: hoffman ew. Clin Cancer Res. 2009 Mar 15;15(6):2166-73. doi: 10.1158/1078-0432.CCR-08-2484. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276262 Clinical Trial.
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J. Nicholaou T, et al. Among authors: hoffman ew. Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23. Cancer Immunol Immunother. 2011. PMID: 21698545 Free PMC article. Clinical Trial.
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
Murphy R, Green S, Ritter G, Cohen L, Ryan D, Woods W, Rubira M, Cebon J, Davis ID, Sjolander A, Kypridis A, Kalnins H, McNamara M, Moloney MB, Ackland J, Cartwright G, Rood J, Dumsday G, Healey K, Maher D, Maraskovsky E, Chen YT, Hoffman EW, Old LJ, Scott AM. Murphy R, et al. Among authors: hoffman ew. Prep Biochem Biotechnol. 2005;35(2):119-34. doi: 10.1081/pb-200054732. Prep Biochem Biotechnol. 2005. PMID: 15881594
46 results